Published in Vaccine Weekly, February 1st, 2006
VIDO is the first in Canada to show that this vaccination technique may be effective against hepatitis C virus (HCV). A report on the group's work was published in the January 2006 Journal of General Virology.
The team, funded by the Canadian Institutes of Health Research (CIHR) and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC), produced a vaccine candidate that decreased the amount of a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.